Developing therapeutics for protein degradation
It is well established that many circulating and membrane proteins of the human secretome can drive a variety of human diseases. Several of these proteins are undruggable using existing approaches. Until now, treatment regimens for these diseases relied upon transfusion, plasmapheresis, immune suppression, or organ removal and/or radioisotope treatment. However, these interventions are not effective or safe. GlycoEra specifically degrades these pathogenic proteins and safely removes from the human body.
GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.
